title: Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.
abstract: 5-HT(1A) receptors mediate some effects of atypical antipsychotic drugs, such as the increase in cortical dopaminergic function, an effect likely related to the superior efficacy of these drugs on negative symptoms and cognitive deficits of schizophrenia. To examine whether 5-HT(1A) receptors are involved in the therapeutic action of clozapine (Clz) on positive symptoms, here we examined the ability of Clz to antagonize the behavioural syndrome induced by the non-competitive N-methyl-d-aspartate receptor antagonist, MK-801 in wild-type (WT) and 5-HT(1A)-receptor knockout (KO(1A)) mice. MK-801 administration induced hyperlocomotion, ataxia, stereotypies and an alteration of the locomotor pattern in both genotypes. However, some symptoms of the behavioural syndrome induced by MK-801 were less intense in KO(1A) mice compared with wild-type mice. Clz antagonized the majority of MK-801-induced effects in both strains of mice. No differences between genotypes were noted for the ability of Clz to antagonize the hyperlocomotion, yet Clz was more effective in preventing the increased activation time, short movements, circling behaviour and hind-limb abduction in KO(1A) mice. The present results indicate that 5-HT(1A) receptors do not play a critical role in Clz-induced antagonism of the main hyperactivity signs evoked by MK-801, suggesting that 5-HT(1A) receptors are not involved in the therapeutic action of Clz on positive symptoms of schizophrenia.
authors.affiliation: Cell Biology Laboratory, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay. scorza@iibce.edu.uy
authors.forename: María Cecilia
authors.initials: MC
authors.lastname: Scorza
authors.forename: Anna
authors.initials: A
authors.lastname: Castañé
authors.forename: Analía
authors.initials: A
authors.lastname: Bortolozzi
authors.forename: Francesc
authors.initials: F
authors.lastname: Artigas
mesh_terms: D000818:Animals; D001259:Ataxia / Q000188:drug therapy / Q000378:metabolism; D003024:Clozapine / Q000494:pharmacology*; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology; D011595:Psychomotor Agitation; D011725:Pyridines / Q000494:pharmacology; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics / Q000378:metabolism*; D058829:Serotonin 5-HT1 Receptor Antagonists; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013239:Stereotyped Behavior / Q000187:drug effects / Q000502:physiology
chemical_list: D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D011725:Pyridines; D058829:Serotonin 5-HT1 Receptor Antagonists; D012702:Serotonin Antagonists; D044282:Receptor, Serotonin, 5-HT1A; D016291:Dizocilpine Maleate; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D003024:Clozapine